Valuation Gedeon Richter LUXEMBOURG S.E.

Stocks

End-of-day quote LUXEMBOURG S.E. 21/10/2026			5-day change	1st Jan Change
39.00 ^USD	-1.02%		+1.04%	+29.14%

10-14	Gedeon Richter Plc. Receives Fda Submission Acceptance of New Drug Application for Fylrevy® in the U.S	CI
09-18	EU Medicines Agency Panel Issues Positive Opinion on Gedeon Richter's Arthritis Drug	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,619,625	1,542,290	1,627,029	1,893,161	1,799,226	2,309,064	-	-
Change	-	-4.77%	5.49%	16.36%	-4.96%	28.34%	-	-
Enterprise Value (EV) ¹	1,559,769	1,395,557	1,546,536	1,782,343	1,588,618	2,046,588	1,899,053	1,772,085
Change	-	-10.53%	10.82%	15.25%	-10.87%	28.83%	-7.21%	-6.69%
P/E	11.6x	9.94x	10.2x	7.96x	7.76x	9.31x	7.97x	7.37x
PBR	1.78x	1.47x	1.44x	1.49x	1.31x	1.54x	1.39x	1.26x
PEG	-	0.9x	3.41x	0.2x	-2.82x	1.34x	0.5x	0.91x
Capitalization / Revenue	2.57x	1.92x	2.02x	2.21x	1.94x	2.43x	2.26x	2.11x
EV / Revenue	2.47x	1.74x	1.92x	2.08x	1.71x	2.15x	1.86x	1.62x
EV / EBITDA	8.86x	7.1x	6.43x	5.74x	4.5x	5.57x	4.79x	4.17x
EV / EBIT	11.5x	9.09x	8.15x	6.82x	5.42x	6.77x	5.7x	4.94x
EV / FCF	-460x	12.3x	17.9x	8.26x	7.56x	9.06x	8.28x	7.16x
FCF Yield	-0.22%	8.12%	5.6%	12.1%	13.2%	11%	12.1%	14%
Dividend per Share ²	225	390	-	-	-	603.6	677	738.7
Rate of return	2.58%	4.7%	-	-	-	4.77%	5.35%	5.83%
EPS ²	751	835	860	1,307	1,271	1,359	1,589	1,718
Distribution rate	30%	46.7%	-	-	-	44.4%	42.6%	43%
Net sales ¹	630,595	802,755	805,158	857,545	928,962	951,368	1,020,834	1,093,689
EBITDA ¹	176,123	196,480	240,625	310,678	353,314	367,576	396,366	425,015
EBIT ¹	135,832	153,555	189,817	261,157	292,851	302,220	332,887	359,032
Net income ¹	139,626	155,581	158,850	239,244	232,335	254,304	290,549	314,929
Net Debt ¹	-59,856	-146,733	-80,493	-110,818	-210,608	-262,476	-410,012	-536,980
Reference price ²	8,725.00	8,300.00	8,750.00	10,400.00	9,865.00	12,660.00	12,660.00	12,660.00
Nbr of stocks (in thousands)	185,630	185,818	185,946	182,035	182,385	182,391	-	-
Announcement Date	02/03/22	28/02/23	29/02/24	07/04/25	27/02/26	-	-	-

¹HUF in Million²HUF

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	36.67x	13.07x	27.74x	0.54%	1,133B
JOHNSON & JOHNSON	37.73x	6.36x	17.89x	2.07%	621B
ABBVIE INC.	36.35x	8.36x	17.26x	2.41%	503B
ROCHE HOLDING AG	21.21x	5.12x	12.74x	2.55%	379B
MERCK & CO., INC.	109.25x	6.09x	26.14x	2.27%	370B
NOVARTIS AG	21.57x	5.62x	13.82x	2.84%	292B
ASTRAZENECA PLC	22.08x	4.46x	12.77x	1.98%	262B
AMGEN INC.	27.83x	7.14x	12.79x	2.3%	237B
GILEAD SCIENCES, INC.	-44.76x	6.88x	26.67x	2.15%	190B
Average	29.77x	7.01x	18.64x	2.12%	443.11B
Weighted average by Cap.	35.57x	8.27x	20.36x	1.81%